Pembrolizumab-associated primary hypothyroidism followed by central hypothyroidism: a case report
PD-1 inhibitors are widely used anticancer drugs and frequently trigger immune-related adverse events, with thyroid dysfunction as the most prevalent. Suspected isolated central hypothyroidism emerging during PD-1 inhibitor therapy has rarely been documented. A 56-year-old man received pembrolizumab for esop...